Literature DB >> 11211914

Animal models of bronchial asthma.

I Szelenyi1.   

Abstract

Due to the continuous increase in prevalence and morbidity in asthma, there is an urgent need to improve present therapy by drugs with new modes of actions. In contrast to many human diseases, allergic asthma does not occur in the animal world. Therefore, we have to mimic some characteristic feature of asthma in animals. For this reason, a wide variety of animal models have been developed and are employed in the search for new chemical entities for asthma therapy. In the present paper, the experimental models of the most characteristic asthma symptoms are critically reviewed.

Entities:  

Mesh:

Year:  2000        PMID: 11211914     DOI: 10.1007/s000110050642

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  15 in total

1.  Reactivity of equine airways--a study on precision-cut lung slices.

Authors:  J Vietmeier; F Niedorf; W Bäumer; C Martin; E Deegen; B Ohnesorge; M Kietzmann
Journal:  Vet Res Commun       Date:  2007-01-24       Impact factor: 2.459

2.  TNF alpha reduces tachykinin, PGE2-dependent, relaxation of the cultured mouse trachea by increasing the activity of COX-2.

Authors:  Ofir Bachar; Andrew C Rose; Mikael Adner; Xudong Wang; Clodagh E Prendergast; Ashley Kempf; Nigel P Shankley; Lars-Olaf Cardell
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

3.  Modulation of the IL-23/IL-17 axis by fenofibrate ameliorates the ovalbumin/lipopolysaccharide-induced airway inflammation and bronchial asthma in rats.

Authors:  Samah M Elaidy; Soha S Essawy; Mona A Hussain; Mohamed K El-Kherbetawy; Eman R Hamed
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-12-30       Impact factor: 3.000

4.  An assay to evaluate the long-term effects of inflammatory mediators on murine airway smooth muscle: evidence that TNFalpha up-regulates 5-HT(2A)-mediated contraction.

Authors:  Mikael Adner; Andrew C Rose; Yaping Zhang; Karl Swärd; Mikael Benson; Rolf Uddman; Nigel P Shankley; Lars-Olaf Cardell
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection.

Authors:  Patrick Carius; Justus C Horstmann; Cristiane de Souza Carvalho-Wodarz; Claus-Michael Lehr
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Airway-specific recruitment of T cells is reduced in a CD26-deficient F344 rat substrain.

Authors:  J Schade; A Schmiedl; A Kehlen; T Z Veres; M Stephan; R Pabst; S von Hörsten
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

7.  Key role of water-insoluble allergens of pollen cytoplasmic granules in biased allergic response in a rat model.

Authors:  Oussama R Abou Chakra; Jean-Pierre Sutra; Pascal Poncet; Ghislaine Lacroix; Hélène Sénéchal
Journal:  World Allergy Organ J       Date:  2011-01       Impact factor: 4.084

8.  Qingfei Xiaoyan Wan alleviates asthma through multi-target network regulation.

Authors:  Zhenying Zhao; Yingbo Miao; Pengwei Pan; Binfeng Cheng; Gang Bai; Hong Wu
Journal:  BMC Complement Altern Med       Date:  2013-08-06       Impact factor: 3.659

Review 9.  Animal models of allergic asthma.

Authors:  Heidi Isenberg-Feig; J Paul Justice; Andrea Keane-Myers
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919

Review 10.  Microbiome and Asthma: What Have Experimental Models Already Taught Us?

Authors:  R Bonamichi-Santos; M V Aun; R C Agondi; J Kalil; P Giavina-Bianchi
Journal:  J Immunol Res       Date:  2015-07-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.